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“Run when you can, 
 walk if you have to, 
 crawl if you must; 
 just never give up.” 
(Dean Karnazes) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EIN KLEINER EINBLICK IN DIE KREBSENTSTEHUNG UND 
DIE ROLLE DER MAKROPHAGEN UND MIKROGLIA 
Krebs ist die zweithäufigste Todesursache weltweit und je älter wir werden, desto 
wahrscheinlicher ist es daran zu erkranken. Diese Krankheit macht vor Niemandem halt; ob 
Frau, ob Mann, ob alt, ob jung. Jeden kann es treffen und zu jedem Zeitpunkt im Leben. Am 
Anfang einer Behandlung stellt sich immer die Frage: „Kann ich den Kampf gegen den Krebs 
gewinnen?“ Und am Ende einer jeden Behandlung bleibt die Unsicherheit: „Habe ich den 
Kampf gegen den Krebs gewonnen?“ Zu Recht, denn es kann passieren, dass vereinzelte sehr 
resistente Krebszellen dem Tod entrinnen konnten und auf der Lauer liegen, damit sie später 
wieder zuschlagen können......und diesmal stärker als zuvor. Ein Kampf, der zu häufig 
verloren wird. 
Was aber ist Krebs? Einfach beschrieben sind es Zellen, die unkontrolliert wachsen. Was 
macht diese Krankheit dann so gefährlich?  
Fangen wir von vorne an. Der menschliche Körper stellt ein System dar, in dem alle Prozesse 
nahezu perfekt aufeinander abgestimmt sind. In diesem System gibt es sehr viele 
verschiedene Kontrollinstanzen, die versichern, dass die Zellen funktionsfähig sind und ihre 
Aufgaben richtig erfüllen. Sollte das nicht mehr der Fall sein, kann unter anderem ein 
„Selbsttötungsprogramm“ eingeleitet werden. Dieser programmierte Zelltod ist in jeder Zelle 
gespeichert, so dass jede Zelle ihn durchlaufen kann, um sicher zu stellen, dass alle Abläufe 
im Körper weiterhin reibungslos verlaufen. Sei es die Eliminierung von überflüssigen Zellen 
während der embryonalen Entwicklung, ein Fehler in der DNA durch UV-Strahlung oder 
einfach nur die Erneuerung von Zellen; die Zelle weiß, wann sie zu gehen hat und Platz 
schaffen muss für eine neue gesunde Zelle. Die Entstehung einer neuen Zelle wird durch den 
Reparaturapparat streng kontrolliert, so dass sichergestellt wird, dass die DNA fehlerfrei ist 
und die Zelle ihre Erlaubnis bekommt zu leben.     
Das Problem entsteht, wenn sich zu viele Fehler in der DNA summieren, die verschiedenen 
Kontrollinstanzen diese Fehler übersehen und sogar selber Defekte aufweisen. Das ist der 
Zeitpunkt, wo die Zellen dem Stoppsignal zum unkontrollierten Wachstum und sogar dem 
Selbsttötungsprogramm entgehen. Es bildet sich eine wuchernde und immer größer werdende 
Zellmasse, die sich unendlich oft teilen kann und unsterblich zu sein scheint. Diese Zellen 
schmeißen die ganzen kontrolliert ablaufenden Prozesse über einen Haufen....wachsen und 
wachsen. Wenn die Zellmasse eine bestimmte Größe erreicht hat, braucht sie die Neubildung 
von Blutgefäßen um weiter wachsen zu können. Wie sonst soll sie Sauerstoff und Nährstoffe 
bekommen, die sie zum Überleben braucht? Wachstumsfaktoren werden im Übermaß 
ausgeschüttet, welche dazu führen, dass die neugebildeten Blutgefäße im Übermaß und 
unorganisiert wachsen. Diese Blutgefäße sind gekennzeichnet durch undichte Stellen und 
eine schlechte Durchblutung. Wenn nun diese Zellen in benachbartes Gewebe eindringen und 
durch die undichten Stellen in den Blutgefäßen zu entfernten Organen gelangen, werden sie 
zu bösartigen Krebszellen. Diese breiten sie sich unkontrolliert im Körper aus, sie streuen, 
und die Entstehung von neuen unkontrolliert wachsenden Zellmassen beginnt, den 
Metastasen. Krebs wird zu einer lebensbedrohlichen Krankheit.  
Doch wo bleibt das Immunsystem? Das Immunsystem ist eins der elementarsten Funktionen 
im menschlichen Körper, das sehr komplex und auf einander abgestimmt ist. Es schützt uns 
vor gefährlichen Eindringlingen und stellt sicher, dass eigene entartete Zellen zerstört 
werden. Diese Aufgaben verlangen das Zusammenspiel von vielen verschiedenen 
Mitgliedern, wozu auch die Immunzellen zählen. Diese Immunzellen sind auch als weiße 
Blutkörperchen bekannt und unter ihnen befinden sich die Makrophagen. Makrophagen 
zirkulieren in unserem Körper und suchen die Umgebung nach Fremdkörpern ab. Treffen sie 
diese an, fressen sie die Fremdkörper auf, kommunizieren durch das Aussenden von vielen 
verschiedenen Stoffen mit ihrer Umgebung und suchen den Kontakt zu anderen Immunzellen 
auf. Diese und noch viele weitere initiierte Prozesse sorgen dafür, dass die Gefahr eliminiert 
wird. Darüber hinaus spielen sie auch eine wichtige Rolle in anderen Bereichen, die zum 
Erhalt des Gleichgewichts der Körperfunktionen beitragen. Diese sind unter anderem die 
Wundheilung und Reparatur von Gewebe, wo auch das Wachstum von neuen Blutgefäßen 
benötigt wird. Eine Fähigkeit, die Tumorzellen ausnutzen. Makrophagen befinden sich in 
allen Organen und selbst im Gehirn findet man sie. Dort sind sie als Mikroglia bekannt. 
Mikroglia erfüllen ganz spezielle und auf das Nervensystem abgestimmte Aufgaben.   
Makrophagen und Mikroglia, die den Tumor infiltrieren, nennt man auch Tumor-assoziierte 
Makrophagen und Mikroglia (TAMMs). Je nachdem welche Signale sie aus ihrer Umgebung 
bekommen, können sie ein bestimmtes Erscheinungsbild annehmen. Durch ihre Plastizität 
können sie auch schnell zwischen unterschiedlichen Aktivierungszuständen wechseln und so 
viele verschiedene Aufgaben durchführen. Manche davon behindern das Krebswachstum und 
seine Streuung, sie sind anti-tumoral; und andere fördern diese Prozesse, sie sind pro-tumoral. 
In den meisten Fällen eliminiert das Immunsystem (Makrophagen und Mikroglia sind hier 
mit eingeschlossen) entartete Krebszellen, die immer wieder versuchen das Immunsystem zu 
überlisten. Makrophagen und Mikroglia zeigen ein anti-tumorales Erscheinungsbild. Viele 
potenzielle Krebszellen fallen dem Immunsystem zum Opfer, jedoch nicht alle. Irgendwann 
schaffen es die Krebszellen das Immunsystem auszutricksen. Sie bilden Moleküle auf ihrer 
Oberfläche ab, die das Signal „Iss mich nicht“ vermitteln und senden Stoffe aus, die den 
Zerstörungsmodus der Immunzellen unterdrücken. Aus Feinden werden Verbündete. An 
Stelle den Krebs zu bekämpfen, helfen ihm nun Makrophagen und Mikroglia bei der 
Entstehung, beim Wachstum und bei der Streuung; sie sind pro-tumoral. Viele dieser 
Mechanismen sind schon erforscht, aber viele andere warten darauf ergründet zu werden. Das 
ist jedoch leichter gesagt als getan. Krebs ist eine sehr komplexe Krankheit, die in jedem 
Organ etwas anders aussieht und die wir bis zum heutigen Tag immer noch nicht komplett 
verstanden haben. Eine Krankheit, in der sich Makrophagen und Mikroglia als 
zweischneidiges Schwert erweisen können. 
Heutzutage gibt es viele verschiedene Therapiemöglichkeiten und es werden immer mehr 
entwickelt. Und doch verlieren wir zu oft den Kampf gegen den Krebs. Es scheint zu viele 
Hürden zu geben, die es zu überwinden gibt. Man muss z.B. die Medikamente erfolgreich zu 
den Krebszellen befördern, obwohl die Blutgefäße um den Krebs herum durchlässig sind. 
Dann kommt hinzu, dass die Verabreichung eines Medikaments Krebszellen abtötet, die eine 
spezielle Mutation aufweisen. Jedoch bilden Krebszellen eine Resistenz gegenüber dem 
Medikament auf und es gibt genügend andere Krebszellen, die andere Mutationen besitzen. 
Und dann ist da noch das Immunsystem. Es gibt sehr viele verschiedene Ansätze das 
Immunsystem wieder „zurück zu programmieren“, so auch für die Makrophagen und 
Mikroglia. Diese Zellen so zu manipulieren, dass sie wieder anti-tumoral agieren. Eine sehr 
wichtige Erkenntnis bei alledem ist, dass eine Behandlungsmöglichkeit oft nicht ausreicht. 
Eine Kombination mit Einbezug des Immunsystems scheint vielversprechend zu sein. Jedoch 
ist der Weg zur Krebsbekämpfung noch lang. Um irgendwann den vollen Umfang an 
Behandlungsmöglichkeiten in der Krebstherapie nutzen zu können, brauchen wir das Wissen 
über jeden einzelnen Ablauf, der in Verbindung mit der Krebsentstehung, dem 
Krebswachstum und der Streuung steht. Dazu gehört auch die „Fehlfunktion“ des 
Immunsystems dem Krebs als Freund und nicht als Feind zu begegnen. Ich hoffe, dass ich 
mit meiner Doktorarbeit einen kleinen Teil dazu beigetragen habe, diese Krankheit besser zu 
verstehen, insbesondere welche Rolle Makrophagen und Mikroglia darin spielen können.  
  

  
ABSTRACT 
Tumor-associated macrophages (TAMs) are among the most abundant cell types in the tumor 
microenvironment. TAM infiltration is usually linked to tumor progression, metastasis and 
poor clinical outcome in most human cancers. These cells sense a wide range of intra- and 
extracellular signals, such as chemokines and growth factors but also disturbances in pH or 
availability of oxygen. Due to their remarkable plasticity, TAMs can react immediately to 
these signals and acquire or switch to different phenotypes and activation states accordingly. 
For the past decade, TAMs have been recognized as a new therapeutic target. Even though 
diverse monotherapy strategies targeting TAMs have shown limited success, there are many 
different experimental studies that have shown promising results when approaching TAM 
subsets in combination with several other treatments, such as chemotherapies. However, our 
knowledge about the full scope of TAM heterogeneity and function in tumor evolvement and 
invasion is still lacking.  
In trying to improve the understanding about the versatile role of TAMs during tumor 
progression and invasion, several contributions have been made in this thesis. First, we show 
a novel mechanism whereby the TAM population can be skewed to contain mainly anti-
tumoral M1-like Macrophages. Thus, we show that the overexpression of Semaphorin 
(SEMA)3A by tumor cells selectively induced the proliferation of M1-like macrophages and 
decreased the expansion of M2-like macrophages. This resulted in enhanced recruitment and 
activation of cytotoxic CD8+ T lymphocytes and NK cells which in turn inhibited tumor 
growth. Second, we demonstrate that macrophage-derived Vascular Endothelial Growth 
Factor (VEGF)-C improved vessel functionality and thereby decreased pulmonary metastasis 
while tumor-derived VEGF-C increased vessel abnormalization and lung metastasis. Third, 
we elucidated that Cripto-1 vaccination decreased lung metastasis by inducing a humoral 
response leading to activated NK cell killing. Finally, we identified that microglia (resident 
macrophages of the brain) but not bone marrow-derived macrophages (BMDMs) induced 
Platelet-derived growth factor receptor (PDGFR)B expression on glioma cells and thereby 
enhanced their migratory capacity. 
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1 INTRODUCTION 
Prior to 2011, there has been limited attention to the role of the tumor microenvironment in 
tumorigenesis. In 2000, Hanahan and Weinberg introduced six hallmarks of cancer that 
underlined the sequential progression of cells to cancer cells during multiple genetic 
alterations, which by then only involved the tumor cells (1). However, during the last decades 
it has become more and more evident that the tumor microenvironment plays an important 
role. Therefore, in 2011, Hanahan and Weinberg revised the hallmarks of cancer and added 
four additional hallmarks that include cancer-related inflammation and the active 
participation of tumor-associated stromal cells in cancer development (2). 
 
1.1 BREAST CANCER 
Breast cancer is the second most common type of cancer worldwide and the most common 
among women (3, 4). This disease is very heterogeneous and needs to be characterized 
precisely to choose the best treatment options (5). The most useful and important 
characteristics to predict prognosis and responsiveness to treatment have been proven to be 
the anatomical and histological determination (6). Anatomical staging is defined by the TNM 
categories, which are the tumor size (T), lymph node involvement (N) and the existence of 
metastases (M) (7). Histological features include the grading containing information about 
cell proliferation and the receptor status. Based on the receptor expression, breast cancer has 
been divided into four distinct molecular subtypes. These are luminal A, luminal B, HER2-
enriched and basal-like breast cancers (Figure 1) (8).  
 
 
 
 
 
 
 
Figure 1. Molecular subtypes of breast cancer. 
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Basal-like breast cancers overlap with triple-negative breast cancers (TNBC) but it is not the 
same disease. In fact, 20% of TNBC are not basal-like (9). TNBC resembles the most 
aggressive subtype of invasive ductal carcinoma, accounts for around 15-20% of breast 
cancer incidences and is associated with poor prognosis (10-12). TNBC shows higher 
metastatic potential compared to other subtypes and has the main metastatic sites in bone, 
lung, liver and brain (13, 14). Lymph node metastasis is observed less frequently but it is a 
crucial prognostic factor (15, 16). Breast cancer treatment is chosen based on the parameters 
described above and includes surgery, neoadjuvant and adjuvant therapy treatments (4).   
 
1.2 GLIOMA 
Gliomas are the most common primary tumors of the central nervous system (CNS) 
accounting for almost 80% of all malignant primary tumors (17). They include astrocytomas, 
oligodendrogliomas, ependymomas and mixed gliomas with astrocytoma being the most 
common type of gliomas (18). Gliomas can be classified into grades based on malignancy (I-
IV), where grade IV is the most malignant, undifferentiated and invasive occurring type and 
denoted glioblastoma multiforme (GBM) (19). GBMs can arise from primary or secondary 
astrocytomas and together with diffuse (grade II) and anaplastic (grade III) astrocytomas 
most often occur in cerebral hemispheres (20). Primary GBMs arise de novo, while secondary 
GBMs progress slowly from low-grade astrocytomas (19). Grade II and III astrocytomas 
generally harbor a mutation in the cytoplasmic isocitrate dehydrogenase [NADP] (IDH)1, 
while GBMs are mostly IDH1 wildtype (20). Based on gene-expression analyses gliomas can 
be further subdivided into classical, mesenchymal, neural and proneural subtypes (Figure 2) 
(21). Low-grade gliomas are mostly of a neural and proneural subtype, while the classical and 
mesenchymal subtypes occur more frequently in high-grade gliomas (21, 22). The growth 
pattern of gliomas is characterized by tumor extensions and tumor microsatellites growing far 
away from the main tumor mass into the normal brain (23). Conventional therapy for GBMs 
such as surgery, radiation and chemotherapy prolongs survival but is not curative (24). 
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Figure 2. Molecular subtypes of astrocytomas. Adapted from (18).  
 
1.3 THE IMMUNE SYSTEM 
In a living organism, one of the immune system’s primary functions is to resist pathogens. 
This host defense system is composed of the innate and adaptive immune systems. These 
subsystems complement each other and are highly balanced. The interplay between the innate 
and adaptive immune systems is essential to ensure long-lasting protection against infections 
and exhibits high complexity (25).  
The innate immune system consists of the complement system, soluble factors such as 
cytokines, natural killer (NK) cells and phagocytic cells such as macrophages and dendritic 
cells (DCs) (26). Innate immunity enables the body to respond immediately against invading 
microorganisms and provides most of the every day protection. Since this protection is 
incomplete, the body requires adaptive immunity, which is a more sophisticated system. 
Adaptive immunity is tailor-made and antigen-specific against each intruder. Cells of the 
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adaptive immune system, B and T lymphocytes, possess unique antigen receptors, which 
enable them to efficiently eradicate pathogens. Although the adaptive immune response to 
primary infection by a pathogen is slower, the response is more powerful when the pathogen 
is encountered the second time due to long-lived memory B and T lymphocytes (27). This 
two-component immune system shows a complicated and fine-tuned network evolved to 
clear infections efficiently and to protect the host.   
 
1.4 MACROPHAGES AND MICROGLIA 
Macrophages are leukocytes that are found in all tissues in differing abundances performing a 
variety of functions within and between distinct tissues. Although macrophages are mainly 
known for their phagocytic capacity, they are also involved in many other important 
processes that provide homeostasis, inflammation and immunity. In the different tissues, 
macrophages exert substantial functional specialization (28). Macrophages are highly plastic 
cells that adapt quickly to microenvironmental stimuli and have been shown to be able to 
respond effectively to environmental changes (29, 30).  
In the brain, microglia are a unique population of long-lived tissue-resident cells that share 
numerous macrophage markers, such as colony stimulating factor 1 receptor (CSF1R), 
ionized calcium binding adaptor molecule (IBA)1 and F4/80 (31). As macrophages, 
microglia survey their surroundings and, if needed, phagocyte debris, apoptotic cells and 
pathogens. Microglia and macrophages regulate migration, differentiation and survival of 
different cell types. Depending on the activation signal they receive, macrophages and 
microglia produce a number of anti- and pro-inflammatory cytokines and growth factors (32). 
However, microglia differ in several aspects such as origin and gene transcription. 
Transcriptome analyses have revealed over 200 genes, such as Sal-like (Sall)1 and purigenic 
G-protein coupled P2y12 receptor, and several microRNAs that are uniquely expressed by 
microglia (31). This might not seem surprising since the brain has a unique 
microenvironment, where microglia exert very specific and distinct functions to maintain 
CNS integrity. Through these functions, microglia support processes such as neurogenesis, 
neuronal differentiation, migration and maintenance (33-35).  
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1.4.1 Origin and Maintenance 
The origin of macrophages and microglia has been discussed for a long time. Lineage-tracing 
experiments in mice revealed that macrophages and microglia originate from diverse 
lineages. During embryonic development, macrophages derive first from the yolk sac 
followed by hematopoiesis of circulating monocytes in the fetal liver. After birth, 
hematopoiesis in the liver is replaced by bone marrow hematopoiesis, which is by then the 
major source of circulating monocytes (36). However, not all tissue-resident macrophages 
derive from circulating monocytes and persist in adulthood, as the skin, pancreas, liver, 
spleen and brain are populated by yolk sac progenitors, while in the kidneys and lung they 
have a chimaeric origin arising from yolk sac and bone marrow (Figure 3) (37, 38).  
 
Figure 3. Origin and ontogeny of tissue-resident macrophages and microglia. Adapted from (38).  
 
It is important to consider that both microglia and macrophages may reside in the CNS but 
develop independently from each other. In mice, at the eighth day after conception CD45- c-
kit+ erythromyeloid precursors are the earliest yolk sac progenitors that can give rise to 
microglia. Microgliogenesis is dependent on transcriptions factors Pu.1 and Interferon 
regulatory factor (Irf)8, and is modulated by matrix metalloproteinases (MMP)-8 and -9 (39). 
Meningeal macrophages derive from hematopoietic stem cells (HSCs) and turn over rapidly 
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(38). In comparison, microglia survive and renew themselves throughout lifetime without any 
influx of circulating monocytes under physiological conditions (40). Thus, depending on the 
tissue, the maintenance of tissue-specific macrophages and microglia ranges between being 
exclusively embryo-derived, like microglia in the brain, to being constantly replaced by bone 
marrow-derived macrophages (BMDMs), such as lamina propria macrophages, found in the 
intestine (Figure 3) (41, 42). Interestingly, monocytes that infiltrate tissues to replace 
embryonic macrophages by hematopoiesis, as observed in the heart, can adapt and 
differentiate into resident macrophages. This finding underlines that macrophages, 
independent of the origin, can exert similar functions when they receive tissue-specific 
signals (43).  
 
1.4.2 Classification and Activation 
The classification of macrophages and microglia is challenging and many aspects have to be 
taken into account when describing distinct subtypes. It is important to consider the source of 
macrophages and microglia, the system used and the characterization of these cells using 
many different markers. Based on a framework including the phenotype, physiological 
activation and functional activity, macrophages have been classified into two subsets, the 
‘classically activated’ M1 macrophages and the ‘alternatively activated’ M2 macrophages 
(44). 
Macrophages independent of origin                        
In the presence of pathogens, necrosis or pro-inflammatory molecules such as interferon 
(IFN)-y or tumor necrosis factor (TNF)-α, macrophages adopt the M1-like phenotype. They 
release pro-inflammatory cytokines and chemokines (e.g. interleukin (IL)-1, IL-23, 
chemokine (C-C motif) ligand (CCL)8), are angiostatic, produce cytotoxic mediators, such as 
reactive oxygen species (ROS), and are involved in T helper (TH)1-mediated immune 
response (45-48). Their phagocytic capacity allows them to clear the body of debris, 
pathogens and cancer cells. Moreover, they express high levels of major histocompatibility 
complex (MHC) class II molecules that activate the adaptive immune system and recruit T 
lymphocytes by antigen presentation (49, 50). On the other hand, macrophages that respond 
to TH2 cytokines (IL-4, IL-13) acquire the M2-like phenotype. Thereby they down-regulate 
their pro-inflammatory activities and instead produce anti-inflammatory mediators such as 
IL-10 and transforming growth factor (TGF)-β	(51). M2-like macrophages harbor also high 
phagocytic capacity as they are involved in fibrosis, tissue repair and wound healing and 
  15 
promote angiogenesis (52). Even if macrophages have acquired a specific phenotype, due to 
their remarkable plasticity, they react quickly to microenvironmental stimuli and switch 
between the different phenotypes to execute the tasks needed (Figure 4) (49).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Summary of the main macrophage polarization states of activated macrophages. 
Adapted and modified from (53).  
 
Microglia                       
Under homeostatic conditions microglia are known as ‘resting’ or ‘surveillant’ microglia that 
actively screen the CNS to maintain physiological functions (54). As soon as microglia 
encounter disturbances they become activated and adopt either a cytotoxic or neuroprotective 
profile depending on the signals they receive (55). Microglia have been divided into states of 
‘classical activation’, ‘alternative activation’ and ‘acquired deactivation’ similar to that of 
extracranial macrophages (Figure 5) (56). In short, classical activated microglia respond to 
injury and infection producing pro-inflammatory cytokines such as IL-1β, TNF-α, nitric 
oxide (NO), ROS and proteases (57-59). Thereby they upregulate CD11b and IBA1 and start 
to express genes that are associated with antigen presentation such as MHC class II, cluster 
differentiation (CD)80 and CD86, resembling an M1-like phenotype of extracranial 
macrophages (60). Alternatively activated M2-like microglia respond to and release the 
cytokines IL-4 and IL-13 to promote anti-inflammation, tissue repair and the uptake of debris 
by upregulating scavenger receptors, such as Mannose receptor C-type (MRC)1, similarly to 
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extracranial macrophages  (46, 61-63). Importantly, M2-microglia support neuron survival by 
releasing insulin-like growth factor (IGF)-1 (64).   
 
 
 
 
 
 
 
 
 
 
Figure 5. Summary of the main microglia polarization states. Adapted and modified from (65). 
 
As macrophages, microglia are very plastic cells that can switch between different 
phenotypes (66). Furthermore, the binary classification of macrophages and microglia into 
M1- and M2-like phenotypes is not as simplistic as described and includes many fine-tuned 
subtypes. For instance, macrophages and microglia can show expression of both M1- and 
M2-like markers that can be differently balanced depending on the tissue, signal and function 
(66, 67). 
 
1.5 TUMOR IMMUNOLOGY 
It is thought that the first immune response at the early stage of neoplastic progression 
resembles the response to acute tissue injury resulting in the infiltration of inflammatory cells 
(68). If the immune cells fail to eradicate the neoplasm, features of acute inflammation shift 
to features of chronic inflammation within the local tissue that fosters cancer development. 
During the persistent recruitment of immune cells, tumor cells secrete different soluble 
factors that alter the microenvironment and recruit additional myeloid cells and lymphocytes 
(69, 70). Once the immune cells arrive at the tumor site, they are exposed to many different 
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tumor secreted factors (e.g. CCL2, IL-4, IL-10, cytochrome c oxidase subunit (COX)2) that 
skew immune cells from an anti-tumoral phenotype to a pro-tumoral phenotype, so that tumor 
cells can evade immune destruction (71). As a consequence, these pro-tumoral immune cells 
release various molecules like growth factors, angiogenic factors, cytokines and proteases 
that promote tumor growth, invasion and metastatic dissemination (72-74).   
 
1.5.1 Tumor microenvironment 
The tumor resembles an autonomous organ that consists of many different components 
including tumor cells themselves, extracellular matrix (ECM), blood and lymphatic vessels 
and immune-inflammatory cells that represent the tumor microenvironment (TME) (75). The 
release of cytokines, growth factors and hormones by the different players adds another layer 
of complexity in a very dynamic network during tumor progression and metastasis (Figure 
6). The number and heterogeneity of all factors varies in different tumor and cell types and 
therefore it is very important to consider these diversities in anti-cancer therapy (76, 77).     
 
 
 
 
 
 
 
 
 
 
Figure 6. Tumor microenvironment of solid tumors. In the stroma different types of cells and 
molecules contribute to tumor progression and metastasis. Adapted and modified from (78). 
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1.6 TUMOR-ASSOCIATED MACROPHAGES AND MICROGLIA (TAMMS) 
In the tumor microenvironment macrophages and microglia are known as tumor-associated 
macrophages and microglia (TAMMs) deriving from tissue-resident macrophages or 
microglia and from circulating monocytes of the peripheral blood (79). They infiltrate the 
tumor stroma and can represent the most abundant cell type with more than 50% of the tumor 
mass (80). In the majority of cancer types, except for prostate, gastric and colon cancer, high 
infiltration of TAMMs is associated with lower patient survival (81).  
Macrophages                             
Tumor-associated macrophages (TAMs) are major contributors to cancer-related 
inflammation and in a tumor TAMs consist of a heterogeneous population showing both M1- 
and M2-like phenotypes (as described above). During cancer initiation, accumulation of M1-
like TAMs contributes to cancer elimination, known as immune surveillance. The 
accumulation of M1-like TAMs activates cytotoxic lymphocytes and thereby restricts tumor 
growth. However, tumor cells can escape the immune surveillance and secrete 
immunosuppressive factors skewing immune cells from an anti-tumoral to a pro-tumoral 
phenotype (82). Hence, the proportion and abundance of TAMs shifts toward an M2-like 
phenotype during tumor development (83, 84). This is important for tumor progression and 
metastasis as M2-like TAMs express high levels of angiogenic factors, anti-inflammatory 
cytokines and scavenging receptors (85). During the course of tumor growth, TAMs 
constantly undergo phenotypic changes in response to microenvironmental factors (86). In 
fact, depending on the niche, TAMs express different molecules and exert distinct functions. 
For instance, TAMs around blood vessels release pro-angiogenic factors like Vascular 
Endothelial Growth Factor (VEGF)-A to induce tumor angiogenesis, while TAMs at the 
invasive front produce MMP-2 and -9 to degrade ECM proteins and to facilitate tumor 
dissemination (87).  
As mentioned earlier the M1/M2 polarization model is a very simplistic view on macrophage 
phenotypes. In 2014, transcriptome-based network analysis on human macrophages revealed 
a spectrum of different phenotypes upon stimulation of macrophages with diverse activation 
signals (88). Furthermore, the comparison of normal renal tissue with patient samples of clear 
cell renal cell carcinoma using single-cell analysis via mass cytometry identified 17 TAM 
phenotypes. In fact, our group performed single cell sequencing analyses of tumor-associated 
macrophages from a mouse mammary tumor virus-polyoma middle T antigen (MMTV-
PyMT) tumor model and uncovered 9 different subgroups based on the transcriptome. 
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Intriguingly, these phenotypes change dynamically during tumor progression (unpublished 
data).  
 
Microglia                         
Glioma-associated microglia (GAMs) promote glioma growth, invasion, immunosuppression 
and angiogenesis by releasing cytokines, growth factors and enzymes similar to that of 
extracranial macrophages. Microglia within a brain tumor mass show also both M1- and M2-
like phenotypes with the M2-like phenotype becoming the predominant one during tumor 
progression. In glioma patients, high infiltration of CD163+ and CD204+ (human M2-
markers) microglia are associated to poor clinical prognosis (89, 90). The inhibition of 
CSF1R re-educates GAMs from an M2-like phenotype to an M1-like phenotype enhancing 
their phagocytic capacity and impairing tumor-promoting functions (91).  
Even though TAMMs share many characteristics, it is also important to understand the 
differences, since the brain displays a unique microenvironment with special needs. Unless a 
neuropathological condition occurs, it is microglia that reside almost exclusively in the brain. 
The disruption of the blood brain barrier allows the infiltration of monocytes from the 
periphery (92). Comparing the expression profiles of TAMMs from glioma-bearing mice 
with naïve microglia, RNA microarray analysis has revealed a different expression profile for 
around 1,000 transcripts. These TAMMs showed only partial overlap in their expression 
pattern with known signatures from in vitro polarized M1- and M2-like macrophage subtypes 
(93).   
 
1.6.1 Recruitment 
As discussed before, tissue-resident macrophages can arise from distinct populations and 
monocytes can comprise one of this population. The CSF1/CSF1R axis plays an important 
role in monopoiesis and mice deficient in either one of the factors show decreased numbers of 
monocytes in the BM and circulation (94, 95). Immature monocytes are Ly6Chi and become 
upon maturation Ly6Clo, which can occur either in the BM or circulation (96, 97). Blood 
monocytes can be divided into two functional subsets, based on the expression of different 
markers, namely short-lived inflammatory CX3C chemokine receptor1loChemokine (C-C 
motif) receptor2+ (CX3CR1loCCR2+)Ly6Chi monocytes that circulate and are recruited to 
inflamed tissues and long-lived resident CX3CR1hiCCR2-Ly6Clo monocytes. These 
CX3CR1hiCCR2-Ly6Clo monocytes are the precursors for myeloid cells in the tissues under 
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homeostatic conditions and their development is dependent on the orphan nuclear hormone 
receptor transcription factor Nr4a1 (98, 99). Expression of G-coupled receptor for 
sphingosine-1-phosphate (S1PR5) induces the release of patrolling Ly6Clo monocytes from 
the BM (100). These patrolling monocytes crawl along blood vessel walls scanning for 
damage and the presence of pathogens (99).  
Under inflammatory conditions, such as during tumor growth, CCL2 is upregulated and 
recruits Ly6Chi monocytes. These inflammatory monocytes express MHC class II and are 
good antigen-presenting cells (101, 102). However, during tumor progression Ly6Chi 
monocytes can be the precursors for TAM subsets and differentiate into Ly6Cint that give rise 
to MHC class IIlo and MHC class IIhi TAMs. Characterization of these two subsets revealed 
that MHC class IIlo TAMs resemble the M2-like phenotype, are proangiogenic, enriched in 
hypoxia and efficiently suppress T cell proliferation. On the contrary, MHC class IIhi TAMs 
express a repertoire of genes that resembles more an M1-like phenotype and are mainly found 
in normoxic regions (103). The infiltration, differentiation and proliferation of tumor-
infiltrating Ly6Chi monocytes is also dependent on CSF1R signaling since blockage of this 
signaling pathway impairs these functions (104). Indeed, high levels of CSF1 are correlated 
with macrophage infiltration in human metastatic breast cancer (105). Homozygous null 
mutation of CSF1 in a mouse model of breast cancer reduced TAM infiltration and abolished 
tumor progression and dissemination. Overexpression, on the other hand, increased tumor 
growth and metastasis (106). Moreover, inhibition of the CSF1R did not only abrogate TAM 
infiltration but also increased the recruitment of CD8+ T cells resulting in reduced mammary 
and cervical tumor growth (107).  
Microglia                            
Glioma cells secrete several cytokines and chemokines to recruit microglia into the tumor 
mass. For instance, CCL2 is also a major contributor to microglia infiltration as well as 
CX3CL1 that increases the ability for migration and adhesion (108, 109). Furthermore, 
growth factors like glial cell-derived neurotrophic factor (GDNF) and hepatocyte growth 
factor (HGF) have been identified as very potent chemoattractants (110, 111).  
 
1.6.2 In situ Proliferation 
Although macrophages that are involved in inflammation and tumor progression are known 
to be recruited from BMDMs, recent evidence has implied that local proliferation of resident 
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macrophages and microglia also contributes to the expansion during pathological conditions 
(109, 112).  
Macrophages                   
Recent findings show that in an inflammatory context, such as atherosclerosis or during 
infection, local M2-like macrophage proliferation is a key event and leads to the expansion of 
this macrophage subtype (113). During nematode infection, controlled by CSF1, IL-4 drives 
local proliferation of macrophages indicating that proliferation is a feature of a TH2 
inflammation-oriented response (114, 115). Intriguingly, proliferation and recruitment can be 
interlinked as observed in adipose tissue. Here, CCL2 induces macrophage proliferation but 
also monocyte entry into circulation and adipose tissue (116).  
Macrophage proliferation has not only been observed under inflammatory conditions but can 
also be found in a tumor setting. For instance, in the spontaneous MMTVneu mouse model, 
that resembles HER2+ human breast cancer, local proliferation of fully differentiated 
CD11blowF4/80high TAMs is the essential mechanism accounting for the accumulation of 
TAMs under CSF1R-dependent signaling. Monocyte depletion did not affect this TAM 
population (117). The presence of proliferating TAMs in human breast cancer material has 
been correlated to hormone receptor negative tumors, high grade and negative clinical 
outcome (118). Furthermore, we have shown that semaphorin (SEMA) 3A increases M1-like 
macrophage proliferation while it inhibits expansion of M2-like macrophages leading to a 
pro-inflammatory microenvironment that hampers tumor growth in mammary breast cancer 
(119). Interestingly, in a murine pancreatic ductal adenocarcinoma (PDAC) model both 
tissue-resident macrophages and inflammatory monocytes contribute to the local TAM 
population. These populations varied in the expression of cell surface markers and their 
function. While embryonically-derived MHC IIlow TAMs exhibited remodeling capacities 
and thereby fueled PDAC progression, monocyte-derived MHC IIhigh TAMs played an 
important role in antigen presentation (120).     
Microglia                          
In different brain malignancies, depending on the pathological condition, various 
observations have been made regarding microglia proliferation and recruitment of BMDMs. 
For example, acute motor nerve damage triggers microglia expansion but not an influx of 
monocytes (121). On the contrary, in brain tumors, both tissue-resident microglia and 
recruited BMDMs are present. These recruited BMDMs, upon entry, can upregulate 
‘microglia-specific’ genes, such as Cx3cr1. Therefore, both populations contribute to the pool 
of glioma-residing myeloid cells (92, 122). However, glioma cells secrete different factors 
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that were shown to trigger local microglia proliferation, such as CCL2, granulocyte-
macrophage (GM)-CSF, M-CSF and VEGF-A (108, 123, 124). Accordingly, M-CSF/M-
CSF1R paracrine communication between microglia and GBM augmented infiltration of 
microglia and GBM invasion in vivo (125).   
 
1.6.3. Innate-adaptive crosstalk  
Macrophages and Microglia                       
As mentioned earlier, at the early stage of tumor initiation, M1-like TAMMs promote anti-
tumor responses by secreting pro-inflammatory factors such as TNF-α and chemokines like 
(C-X-C motif) ligand (CXCL)9 and CXCL10. The release of these chemokines mediates 
activation and recruitment of cytotoxic T lymphocytes and NK cells that show anti-tumoral 
properties (126). However, M2-like TAMMs lose these anti-tumoral activities (52, 127, 128). 
They secrete immune-suppressive molecules such as IL-10 and TGF-β that down-regulate 
anti-tumoral cytotoxic T lymphocyte and NK cell activity (129, 130). Instead, these TAMMs 
stimulate the differentiation of naïve CD4+ T lymphocytes into TH2 cells and regulatory T 
lymphocytes that augment anti-tumoral activity (Figure 7) (131, 132).  
 
 
 
 
 
 
 
 
 
 
Figure 7. Cross-talk between TAMMs and T cells. M1-TAMMs activate CD8+ T lymphocytes, 
while M2-TAMMs inhibit CD8+ T lymphocytes and activate regulatory CD4+ T lymphocytes.   
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1.6.4 Angiogenesis 
Tumor angiogenesis, triggered by the angiogenic switch, induces the growth of new blood 
vessels from pre-existing vasculature to supply the tumor with oxygen, nutrients and is 
required for the tumor to grow beyond a size of 1-2 mm3 (133-136). Hence, the balance 
between anti- and pro-angiogenic factors shifts toward a pro-angiogenic microenvironment 
(137). Many different factors regulating the angiogenic switch have been reported including 
VEGF-A, TGF-β and ROS (138-140). In fact, hypoxia is a key driver of angiogenesis and the 
secretion of VEGF-A by cancer cells and recruited leukocytes triggers the development of a 
vascular network (135). These tumor blood vessels are characterized by a disorganized 
establishment, excessive vessel branching and enlarged vessels (141, 142). The discontinuous 
lining of endothelial cells and pericytes but also defective basement membranes result in 
leaky and poorly perfused vessels that increase tumor intravasation and hamper drug delivery 
(143, 144).   
TAMMs are key effectors in angiogenesis and are known to accumulate in poorly 
vascularized necrotic areas and to surround blood vessels (145). They switch into the pro-
angiogenic phenotype in the presence of stress factors such as low oxygen, low pH and high 
lactate concentration (146). Hypoxia appears to be one of the strongest factors promoting 
TAMM recruitment (147, 148). Once they have reached the hypoxic sites, hypoxia changes 
gene expression toward pro-angiogenic genes through the modulation of hypoxia-inducible 
factor (HIF)-1 and HIF-2 and other transcription factors (149, 150). In response, TAMMs 
secrete a number of pro-angiogenic growth factors including VEGF-A, CXCL2, TNF-α and 
basic fibroblast growth factor (bFGF) but also matrix modulating mediators such as MMPs, 
urokinase-type plasminogen activator (uPA) and its receptor uPAR (87, 148, 151, 152). For 
instance, MMP-9 expression by microglia increases glioma growth and invasion (153). 
Moreover, inhibition of MMP-9 activity and expression by infiltrating macrophages reduces 
the release of VEGF-A from the ECM and thereby inhibits angiogenesis and tumor growth in 
cervical cancer (154). Interestingly, hypoxia does not seem to drive the M2-phenotype but 
rather fine tunes M2-like TAMMs (155). TAMs that surround blood vessels and promote 
angiogenesis were identified to express the Tie2 receptor (156). Accumulation of Tie2+ 
macrophages is correlated with microvascular density and distant metastasis (Figure 8) (157, 
158).  
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Figure 8. Modulatory functions of macrophages in the tumor microenvironment. Adapted from 
Macrophages: Biology and Role in the Pathology of Diseases, Chapter 7: Vascular Modulatory 
Functions of Macrophages. Ioanna Keklikoglou and Michele De Palma; Editors: Subhra K. Biswas 
and Alberto Mantovani. Springer.  
 
1.6.5 Lymphangiogenesis 
In the embryonic development lymphatic vessels are established after the cardiovascular 
system, when subpopulations of endothelial cells commit to the lymphatic lineage (159). 
Lymphatic capillaries are unidirectional and are lined with a thin single layer of lymphatic 
endothelial cells (LECs) anchored to the ECM (160). These LECs have a discontinuous 
basement membrane and lack the coverage of pericytes or smooth muscle cells that makes 
them highly permeable to interstitial fluids and proteins and facilitates immune cell 
transmigration (161, 162). Hence, the function of lymphatic vessels includes the regulation of 
tissue fluid homeostasis, collection of macromolecules from tissues back to the blood 
circulation as well as the transport of immune cells (162).  
As angiogenesis, lymphangiogenesis in adult tissues only occurs during tissue repair, 
inflammation or tumorigenesis (163). Both VEGF-C and -D are involved in physiological 
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and pathological lymphangiogenesis (164, 165). Whereas the deletion of Vegfd in mice 
results in slight reduction of lymphatic vessels, deletion of Vegfc leads to embryonic lethality. 
Thus, VEGF-C is essential for initial sprouting, migration and survival of LECs (166, 167). 
Tumor-associated lymphatic vessel growth is positively correlated to the overexpression of 
VEGF-C and -D in tumors (168, 169). Tumor-associated lymphatic vessels occur mostly at 
the tumor margin but may also occur intratumoral (169). LECs isolated from normal tissue 
compared to the ones from fibrosarcoma displayed significant differences in the expression of 
790 genes. Among those, genes implicated in endothelial junctions, matrix and vessel growth 
were upregulated, while matrix proteins like collagens and fibrillin were downregulated (170, 
171).  
Lymphangiogenesis is also mediated by several subpopulations including tumor cells, 
stromal cells, activated platelets and infiltrating macrophages (172, 173). TAMs do not only 
secrete the lymphangiogenic factors VEGF-C and -D, they also respond to the chemotactic 
properties of VEGF-C as they express its receptor VEGFR-3 (174). Thus, TAMs have been 
associated with lymphangiogenesis in several studies (172, 175). The accumulation of TAMs 
significantly correlates with lymph vessel density in several tumor tissues (176). In human 
breast cancer, elevated levels of VEGF-C expressing TAMs are not only associated with 
increased lymph vessel density but also with lymph node metastasis and lymph vessel 
invasion (177). Interestingly, mechanistic evidence has been provided for the involvement of 
TNF-α activated TAMs in lymphangiogenesis and lymphatic metastasis. These TAMs 
mediate the observed effects by coordinating VEGF-C/VEGFR-3 signaling (178).     
 
1.6.6 Invasion and Metastasis 
Invasion and metastasis is a multistep process that includes a cascade of different events. 
TAMs are one of the major players as they contribute at various steps (179). In the early stage 
of tumor development, macrophages are found in areas of basement membrane breakdown 
and in advanced tumors at the invasive front (106, 180). Tumor cells exploit the matrix 
deposition and remodeling capacities of TAMs that produce MMPs and other proteolytic 
enzymes (181, 182). For instance, the proteolytic capacity of MMP-9 releases matrix-bound 
VEGF-A that contributes to angiogenesis and metastasis (183, 184). Moreover, it has been 
shown that the release of MMPs by TAMs promotes tumor cell motility and invasiveness 
(148, 185-187). Thus, TAM-derived enzymes help in the establishment of a premetastatic and 
metastatic niche (84).  
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Intravasation also requires close interaction between tumor cells and TAMs. The release of 
CSF1 by tumor cells stimulates migration of CSF1R expressing macrophages and their 
production of epidermal growth factor (EGF) in turn activates invasion of EGFR expressing 
tumor cells. Depletion of either one of the factors of this paracrine signaling loop abrogates 
migration of both cell types in vivo (125, 188). Interestingly, Wyckoff and colleagues could 
show that macrophages guide tumor cells to the blood vessels and thereby increase migration 
and invasion (189). Additionally, TAMs increase tumor cell intravasation by contributing to 
vascular abnormalization creating leaky blood vessels. Thus, macrophage re-education of 
M2-like macrophages to M1-like macrophages inhibits endothelial cell proliferation and 
normalizes the vessel walls, which in turn prevents tumor cell intravasation and metastasis 
(190). However, at the metastatic site tumor cells recruit macrophages to also induce vessel 
permeability via the upregulation of VEGF-A enabling them to extravasate (191). These 
macrophages were characterized as CCR2+VEGFR1+Ly6C-F4/80+ macrophages (192).  
Tumor metastasis to distant organs and lymph nodes is well established. Tumor cells can 
metastasize to one or more distant sites either sequentially or in parallel. (193). However, 
there are still contradictory studies about the role of lymph nodes in metastasis. On one hand, 
it is reported that lymph nodes promote further spreading and on the other hand studies point 
out that lymph nodes only serve as distant sites of tumor cell colonization without any further 
dissemination (194-197). Nevertheless, there is one common consensus about lymph node 
metastasis being a key prognostic marker for patient survival and outcome (198, 199).  
In conclusion, TAMs play an important role in the process of tumor metastasis and high 
infiltration of TAMs is correlated with increased tumor cell dissemination, malignancy and 
tumor grade in many types of cancer (92, 145, 200). 
 
1.7 THERAPEUTIC IMPLICATIONS 
TAMs have emerged as attractive targets in anti-cancer therapy because they are the 
predominant cell type in many different cancers, they contribute in various ways to cancer 
progression and are associated with therapy resistance (73, 201, 202). Importantly, compared 
to cancer cells they are genetically stable and thus less susceptible to acquire therapeutic 
resistance (203). So far, several studies have been conducted targeting TAMs from different 
angels. These include inhibition of macrophage recruitment, macrophage re-education toward 
an anti-tumoral phenotype and suppression of macrophage survival (85, 202).  
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For instance, inhibition of CCL2 or VEGFR-2 reduces the infiltration of macrophages and 
inhibits tumor growth and angiogenesis (204, 205). Another very attractive target to block the 
recruitment of TAMs to tumor sites is the CSF1/CSF1R pathway. Ries and colleagues 
showed that blocking the CSF1R with the monoclonal antibody RG7155 reduces the 
recruitment of CSF1R+CD163+ macrophages to the tumor in patients suffering from diffuse-
giant sarcoma improving their clinical outcome (206). Furthermore, inhibition of CSF1R 
reprograms microglia from a pro-tumoral phenotype to an anti-tumoral phenotype that 
hampers glioma development and increases survival (91). However, CSF1R inhibition as a 
monotherapy does not always succeed. In preclinical models of breast cancer there was only 
an effect in tumor growth suppression when CSF1R inhibition was used in combination with 
other drugs, such as paclitaxel (207, 208). This different outcome points out the important 
fact that the composition of anti-cancer therapy is dependent on the cancer type and location 
and that monotherapy is not sufficient enough as it only delays tumor growth. Therefore, the 
combination with irradiation, anti-angiogenic therapies, adoptive T cell transfer and immune 
checkpoint inhibitors represents attractive partners (209-212).  
Since it is known that M1-like macrophages execute anti-tumoral activity, re-educating pro-
tumoral M2-like macrophages to anti-tumoral M1-like macrophages illustrates another 
attractive strategy. In this respect, several studies have shown anti-cancer potential using this 
approach. Coscia and colleagues have shown that zoledronic acid skews macrophages from 
an M2-like to an M1-like phenotype and thereby inhibits spontaneous mammary carcinoma 
development (213). Moreover, histidine-rich glycoprotein induces the re-education of TAMs 
toward an M1-like phenotype resulting in vessel normalization, increased vessel functionality 
and hampering of tumor growth and metastasis (190).  
Finally, suppression of TAM survival has also been shown to improve therapeutic outcomes. 
Cieslewicz and colleagues developed an M2-like macrophage specific pro-apoptotic peptide 
(M2pep) that selectively killed TAMs in tumor-bearing mice improving their survival rates 
(214).  
All these different approaches display high potential of using TAMs as a target in anti-cancer 
therapy and underline that the microenvironment is an important player to consider in 
successful treatment.  
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2 AIMS OF THE THESIS 
The overall aim of this thesis is to elucidate the diverse functions of tumor-associated 
macrophages and microglia in tumorigenesis and metastasis. Understanding the mechanisms 
of how macrophages and microglia contribute to tumor malignancies in different 
microenvironments helps to develop tools that specifically target distinct subpopulations.  
The thesis consists of the following four studies: 
Study I: Exploring the effect of SEMA3A on the accumulation of anti-tumoral macrophages 
and their anti-tumor activity in mouse and human breast cancer. 
Study II: Elucidating the role of macrophage- and tumor-derived VEGF-C on tumor 
metastasis in mouse and human breast cancer. 
Study III: Studying the effect of Cripto-1 vaccination on metastasis and cancer stem cells in 
mammary carcinoma. 
Study IV: Examining the function of macrophages and microglia in PDGFB-driven mouse 
and human glioma.  
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3 RESULTS AND DISCUSSION 
3.1 TUMOR MOUSE MODELS 
TAMMs, major players in tumor progression and metastasis, can be of an anti- or pro-
tumoral phenotype that can either restrict or fuel tumor development at various steps. In this 
thesis we have investigated the anti- and pro-tumoral properties but also functional 
differences of TAMMs in breast cancer and glioma.  
In study I-III we used the 4T1 mammary tumor mouse model to investigate tumor-
associated macrophages and tumor cells in breast cancer evolvement and dissemination. 4T1 
tumor cells were originally isolated from a single spontaneous tumor that arose in a 
BALB/cfC3H mouse and resembles human TNBC (215, 216). We engineered the cell line 
according to our aims to either overexpress SEMA3A, VEGF-C or cripto-1 and injected the 
cells orthotopically into the mammary fat pad of mice.  
There are several advantages of using 4T1 tumor cells to study breast cancer. First, it is an 
easy transplantable cell line that is highly tumorigenic and invasive. As it is injected into the 
mammary fat pad it grows in the anatomically correct site. Second, 4T1 tumor cells 
spontaneously metastasize from the primary tumor mainly via the hematogeneous route to 
lung, liver, brain, bone and blood and to a lesser extent to the lymph nodes. Thus, 4T1 tumor 
cell dissemination is similar to that of human breast cancer. Finally, 4T1 tumor cells are 
resistant to 6-thioguanine enabling the quantification of metastasis in the mentioned distant 
organs (217). Of note, this model displays high accumulation of granulocytes into the tumors 
and lungs, which is a dissimilarity to human TNBC.   
In Study IV we expanded our knowledge about macrophages by elucidating the functional 
role of microglia and their difference to macrophages in glioma development. We used the 
RCAS/tv-a mouse glioma model. Mice of this model harbor two genetic aberrations 
including the systemic depletion of the tumor suppressor Arf and the expression of the tv-a 
gene in glial progenitor cells that contain the nestin promoter. The tv-a gene encodes the 
receptor for the avian leukosis virus (ALV) and is normally only expressed in avian cells. The 
viral vector RCAS that is derived from the same virus is packaged with pdgfb and newborn 
mice are transduced with this virus allowing the selective transduction of glial progenitor 
cells that harbor the nestin promoter. Thus, those mice develop PDGFB driven N/tv-a;Arf-/- 
gliomas at high rates up to 100% incidence at 12 weeks of age (218, 219). This glioma model 
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is a well established and widely used model to study the mechanisms of glioma development 
and provides a life-like model of human glioma of grade II to IV (219).    
 
3.2 STUDY I 
Guidance molecule SEMA3A restricts tumor growth by differentially regulating the 
proliferation of tumor-associated macrophages 
Semaphorin (SEMA)3A is a secreted protein that was originally discovered as an axon 
guidance regulator in establishing the neuronal network in the embryonic nervous system 
(220, 221). This protein is found in most human tissues and binds to its co-receptor neuropilin 
(NP)1 that forms receptor complexes with receptors of the Plexin family (222). However, in 
the last decade SEMA3A has been implicated in cancer development. Except for pancreatic 
cancer, where SEMA3A expression has been positively correlated to increased malignancy 
grade, this protein is down-regulated in several human cancers such as breast, gastric, 
epithelial ovarian and non-small cell lung cancer (119, 223-226).  
Animal studies investigating the effect of SEMA3A on macrophages in the tumor 
microenvironment show contradictory results. Carrer and colleagues demonstrated that 
SEMA3A promotes vessel maturation through the recruitment of circulating NP1 expressing 
monocytes. These CD11b+NP1+Ly6G- monocytes, isolated either from the bone marrow or 
from SEMA3A-expressing muscles and directly injected into growing tumors, exerted anti-
tumoral activity by induction of vessel normalization and inhibition of tumor growth (227). 
On the other hand, Casazza and colleagues reported that SEMA3A is induced in hypoxic 
areas and acts as an attractant for NP1-expressing TAMs. Once those TAMs have arrived in 
the hypoxic environment, they are entrapped inside the hypoxic niche and exert pro-
angiogenic and immune-suppressive functions promoting tumor growth and metastasis (228).  
However, knowing that SEMA3A expression is down-regulated in many different human 
cancer types, we also checked SEMA3A expression levels in different grades of human 
breast cancer samples. In concordance, we found a down-regulation of SEMA3A with 
disease progression. To further study the effect of SEMA3A on tumor development, we used 
the 4T1 tumor mouse model with 4T1 cells that overexpressed SEMA3A. Tumors 
overexpressing SEMA3A showed reduced tumor growth and burden. When we dissected the 
tumors and looked at the immune cell composition, we discovered an increased accumulation 
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of anti-tumoral M1-like macrophages and cytotoxic lymphocytes including T lymphocytes 
and NK cells. 
The M1- and M2-like phenotypes of macrophages were determined by the expression of 
different cell surface markers using flow cytometry and gene expression profiles via RT-
qPCR. Using flow cytometry we classified macrophages as CD11b+Ly6G- cells. On the basis 
of MHC class II expression we further subdivided macrophages into Ly6Clo MHC class IIhi 
M1-like macrophages and Ly6Clo MHC class IIlo M2-like macrophages. Additionally, we 
further verified our observation by investigating M1- and M2-markers that are involved in 
costimulation, antigen presentation and scavenging including CD11c, CD80, CD86, MHC 
class I and MRC1 in CD11b+F4/80+ macrophages. Sorted CD11b+F4/80+ macrophages from 
SEMA3A and CTR tumors were subjected to RT-qPCR looking at a range of cytokines and 
growth factors confirming our result of increased M1-like macrophage accumulation in 
SEMA3A tumors. 
Based on our results and the fact that tumors are infiltrated by monocytes, we speculated that 
monocyte recruitment might account for the observed effect. However, there was no increase 
in monocyte frequency in the blood or tumor in SEMA3A overexpressing tumors. 
Furthermore, direct administration of SEMA3A to BMDMs did not affect their phenotype. 
Interestingly, publications about local macrophage proliferation led us to investigate if 
SEMA3A affected proliferation rather than recruitment of M1- and M2-like macrophages. 
Indeed, we could show both ex vivo and in vivo that SEMA3A mediates the expansion of M1-
like macrophages, while it reduces the proliferation of M2-like macrophages. This effect was 
NP1 dependent and regulated Akt and MAPK signaling. Intriguingly, knockdown of NP1 in 
BMDMs mimicked the effect of SEMA3A on Akt and MAPK phosphorylation mediated by 
CSF1 stimulation. Thus, CSF1 stimulated M1-BMDMs showed increased Akt and MAPK 
phosphorylation after SEMA3A treatment or NP1 inhibition, while M2-BMDMs displayed 
reduced Akt and MAPK phosphorylation. NP1 can undergo signaling complexes with 
various members of the Plexin A family and therefore, we speculate that differential 
expression of Plexin A receptors and diverse dimerization complexes with NP1 could induce 
the opposing outcome in M1- and M2-macrophage proliferation. Further investigations are 
needed to explore the detailed mechanism of SEMA3A-mediated macrophage proliferation. 
However, SEMA3A overexpressing tumors did not only show accumulation of anti-tumoral 
macrophages but also of cytotoxic CD8+ T lymphocytes and NK cells. The increased 
recruitment and activation of CD8+ T lymphocytes and NK cells was dependent on and 
mediated by SEMA3A via NP1 expression on macrophages. Nevertheless, the observed 
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reduced tumor growth of SEMA3A tumors was attributed to both macrophages and cytotoxic 
cells. Accordingly, upon depletion of the different populations SEMA3A lost its effect on 
tumor growth inhibition.   
In sum, we show that SEMA3A mediates the proliferation of M1-like macrophages that 
creates a more pro-inflammatory microenvironment enhancing the recruitment and activation 
of cytotoxic CD8+ T lymphocytes and NK cells and thereby inhibiting breast cancer 
progression (Figure 9). 
 
Figure 9. SEMA3A enhances the expansion of M1-like macrophages and restricts the proliferation of 
M2-like macrophages. The selectively regulated proliferation recruits and activates cytotoxic CD8+ T 
lymphocytes and NK cells and thereby inhibits tumor progression.  
 
 
3.3 STUDY II 
Macrophage-derived Vascular Endothelial Growth Factor-C decreases hematogeneous 
metastatic dissemination by normalizing the tumor vasculature 
 VEGF-C is a secreted dimeric glycoprotein and one of five family members in mammals 
(229). In adults VEGF-C expression is found in many different organs including heart, lung, 
pancreas and kidneys (230, 231). VEGF-C can bind to its two receptors VEGFR-2 that 
interacts with the co-receptor NP1 and VEGFR-3 that binds NP2 (230, 232, 233). The 
affinity of VEGF-C to either one of the receptors depends on the proteolytic cleavage. While 
non-processed VEGF-C activates VEGFR-3 signaling, mature VEGF-C binds with high 
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affinity to both VEGFR-2 and -3 and can induce the formation and activation of receptor 
heterodimers (Figure 10). These heterodimers have been reported to be present on lymphatic 
vessels but also on angiogenic sprouts pointing out a bimodal function for VEGF-C and its 
receptors (234-236). In fact, a study conducted by Tammela and colleagues showed that 
Tie2+VEGF-C+-macrophages accumulate behind tip cells at vascular branching points 
inducing endothelial cell differentiation via VEGFR-3 and Notch signaling. Thus, this finding 
indicates a function of VEGF-C-expressing macrophages in vessel maturation (237). Of note, 
processing of VEGF-C also affects its binding to the two co-receptors NP1 and NP2. While 
the partially processed protein binds to both NP1 and NP2, only the fully mature protein can 
bind NP2 showing another layer of complexity in VEGF signaling (238).  
 
 
 
 
 
 
 
 
Figure 10. VEGF-C binding specificities and VEGFR signaling complexes. Adapted and modified 
from (239). 
 
However, VEGF-C expression has been detected in several different types of human tumors 
including breast, cervix, colon, lung, prostate and stomach (240-242). Although VEGF-C 
expression is predominantly correlated to lymphangiogenesis, it has been shown that tumor 
cell-secreted VEGF-C binds to VEGFR-3 that is upregulated on angiogenic blood vessels in 
breast cancer (243-245). Several different types of tumors express VEGF-C but TAMs have 
been reported to be a major source of this protein and as mentioned before they correlate to 
lymphatic microvessel density, lymphangiogenesis, invasion and lymph node metastasis in 
several types of cancer (172, 174, 177, 246, 247). 
 
 
NP1 NP2 
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As tumor dissemination occurs later during cancer progression and macrophages are active 
participants in this process, it would be natural to assume that macrophages and tumor cells 
secrete increased levels of VEGF-C leading to lymph node metastasis in advanced breast 
cancer. However, when we looked at VEGF-C expression in ER+ grade I and III ductal 
carcinoma and grade III TNBC, we found unexpectedly decreased VEGF-C expression by 
CD68+ macrophages in grade III compared to grade I breast cancer. Moreover, the overall 
expression of VEGF-C within the tumor seemed to be similar throughout the different grades. 
This evidence prompted us to further investigate if tumor- and macrophage-derived VEGF-C 
might be differentially regulated during tumor progression and thereby influence the route of 
tumor cell dissemination.  
To investigate our hypothesis we chose to use the 4T1 tumor mouse model. As mentioned 
earlier this mouse model resembles TNBC and mainly metastasizes via the hematogeneous 
and not lymphangiogenic route. Accordingly, we expected high levels of VEGF-A in 
macrophages and tumor cells. Therefore, macrophages and tumor cells were sorted from 4T1 
tumors and VEGF-A, -C and -D expression levels were analyzed by RT-qPCR. Intriguingly, 
macrophages only expressed VEGF-A while VEGF-C and -D were undetected. However, 
tumor cells expressed both VEGF-A and VEGF-C to a similar extent. Nevertheless, it was 
evident that macrophages expressed 10 times higher levels of VEGF-A compared to tumor 
cells, so that we speculated that macrophage-derived VEGF-A rather than tumor-derived 
VEGF-A dictates the preferred hematogeneous route for 4T1 cancer cell dissemination. We 
further hypothesized that if we engineer macrophages to overexpress VEGF-C, we might be 
able to change the preferable route of dissemination from blood vessels to lymphatic vessels.  
To test our theory, we engineered chimeric mice that had been transplanted with bone 
marrow-derived stem cells to express VEGF-C using lentiviral-mediated gene transduction. 
These chimeric mice were then inoculated with 4T1 tumor cells. In comparison, to test what 
effect tumor-derived VEGF-C has, 4T1 tumor cells were also engineered to overexpress 
VEGF-C by lentiviral-mediated gene transduction and injected into the fat pad of naïve mice. 
Neither macrophage- nor tumor-derived VEGF-C altered tumor growth or burden compared 
to their respective controls. However, tumor- and macrophage-derived VEGF-C had a 
different effect on lung metastasis. While both tumor- and macrophage-derived VEGF-C 
increased lymph node metastasis, only macrophage-derived but not tumor-derived VEGF-C 
decreased lung metastasis. In fact, tumor-derived VEGF-C increased pulmonary metastasis 
but not as a consequence of increased angiogenesis. Consequently, we considered another 
important factor contributing to tumor spreading, namely vessel dysfunctionality. Therefore, 
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we determined blood vessel perfusion, pericyte coverage and hypoxia. Interestingly, 
macrophage-derived VEGF-C increased vessel perfusion, pericyte coverage and decreased 
hypoxia while tumor-derived VEGF-C had the opposite effect. Improved vessel functionality 
is attributed to the M1-like phenotype but VEGF-C expression in macrophages or tumor cells 
did not shift the macrophage phenotype toward an M1- or M2-like phenotype. Moreover, 
neither the infiltration of cytotoxic CD8+ T lymphocytes nor NK cells was altered. Further 
investigations are necessary to elucidate the exact mechanism of improved vessel 
functionality by macrophage-derived VEGF-C. It would be interesting to elaborate if 
processing of VEGF-C and the binding to its two receptors VEGFR-2 and -3 is regulated 
differentially by tumor cells and macrophages leading to the various effects on vessel 
functionality.  
Taking all results in perspective, we show that macrophage-derived VEGF-C normalizes the 
tumor vasculature and thereby decreases pulmonary metastasis while tumor-derived VEGF-C 
increases vessel abnormalization and lung metastasis (Figure 11).  
 
Figure 11. Macrophage-derived VEGF-C normalizes the blood vessels and thereby decreases lung 
metastasis, while tumor-derived VEGF-C decreases vessel functionality leading to increased 
pulmonary metastasis. 
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3.4 STUDY III 
Cripto-1 plasmid DNA vaccination targets metastasis and cancer stem cells in murine 
mammary carcinoma    
Cripto-1 is a protein that plays an important role during embryonic development contributing 
to the undifferentiated status of human and mouse embryonic stem cells (248). However, 
more than 50% of human cancers, including breast cancer, show elevated Cripto-1 expression 
levels and its presence on cancer cells has been associated with the cancer stem cell (CSC) 
phenotype (249, 250). CSCs are a subpopulation that initiates tumor growth, shows enhanced 
metastatic potential, is resistant to radiation and chemotherapy and responsible for relapse 
(249, 251). Indeed, cripto-1 has been shown to be involved in proliferation, angiogenesis and 
invasion and high levels are associated with colorectal metastasis and poor prognosis in colon 
and breast cancer (252-256). Therefore, Cripto-1 displays an interesting candidate to 
specifically target metastatic cancer cells. For instance, in a murine melanoma model Cripto-
1 vaccination elicited a specific cytotoxic CD8+ T lymphocyte mediated protective response 
by reducing primary tumor burden and lung metastasis (257). 
Hence, we wanted to investigate if Cripto-1 vaccination also had a protective effect in 
mammary breast cancer progression and metastasis. Therefore, different cell lines were 
checked for Cripto-1 expression. Cripto-1 could be detected in the highly metastatic 4T1 
tumor cell line and in TUBO cells that show a cancer stem cell like phenotype. However, 
Cripto-1 expression in 4T1 cells was very low and not detectable via flow cytometry, so that 
we decided to generate a stable Cripto-1 expressing 4T1 cell line that could be used in our in 
vivo studies. Before inoculation of these cells into the mammary fat pad, mice were 
vaccinated with Cripto-1 encoding DNA plasmids. Intriguingly, Cripto-1 vaccination did not 
only reduce tumor growth and burden but also decreased lung metastasis.  
We then wondered how this effect was mediated. Vaccination goes along with cell- and 
antibody-mediated immunity. Accordingly, we speculated that Cripto-1 vaccination could 
evoke a humoral response in mice. Indeed, we detected Cripto-1 specific antibodies in serum 
of vaccinated mice that could bind to Cripto-1 expressing 4T1 cells. Moreover, most of the 
antibodies belonged to the subclasses IgG2a and IgG2b that in mice mediate antibody-
dependent cell-mediated cytotoxicity (ADCC) by NK cells. To test if Cripto-1 specific 
antibodies induce ADCC, we investigated if serum from Cripto-1 vaccinated mice could 
increase NK cell cytotoxicity. In fact, pre-activated NK cells showed increased lysis of 
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Cripto-1 expressing 4T1 cells in the presence of serum from Cripto-1 vaccinated mice in 
vitro.  
Furthermore, to verify our observations of reduced tumor and metastatic burden in our 
validation model (Cripto-1 expressing 4T1 tumor mouse model), we used the more clinical 
relevant BALB-neuT mouse model. Intriguingly, despite Cripto-1 negative primary tumors, 
we observed a protective effect of Cripto-1 vaccination on the metastatic burden in the lungs. 
Furthermore, Cripto-1 vaccination effectively decreased tumor growth of TUBO cells that 
show CSC characteristics and even led to tumor clearance, as three out of eleven mice stayed 
tumor free for more than 60 days.  
Taking all together, Cripto-1 vaccination induced a humoral response facilitating NK cell-
mediated ADCC and the reduction of lung metastasis (Figure 12).  
 
Figure 12. Cripto-1 DNA plasmid vaccination decreases the metastatic burden in lungs of mice 
harboring Cripto-1 positive and negative primary tumors. NK cells show enhanced killing of Cripto-1 
expressing 4T1 tumor cells in the presence of Cripto-1 serum. 
 38 
3.5 STUDY IV 
Microglia induce PDGFRB expression in glioma cells to enhance their migratory 
capacity                  
Platelet-derived growth factor (PDGF)B and one of its receptors, PDGFRB, are essential for 
physiological processes like proliferation, migration and blood vessel development but have 
also been linked to pathological conditions, such as glioma development (258-260). This 
signaling pathway is mostly linked to tumor-associated vasculature and angiogenesis. For 
instance, PDGFB expression by endothelial cells regulates vessel permeability and vascular 
maturation in extracranial solid tumors (260, 261). Moreover, tumor cells that overexpress 
PDGFB induce displacement of PDGFRB+ pericytes from endothelial cells, which increases 
vessel dysfunctionality and metastatic dissemination (262). However, even though not one of 
the most prevalent alterations, aberrations in PDGFB expression and/or PDGFRB 
phosphorylation are observed in gliomas and GBMs (218, 260, 263). Interestingly, there is 
one study reporting that PDGFRB is commonly expressed in cultured patient-derived GBM 
cells, especially by self-renewing GBM stem cells (264).  
At the time when this study was initiated PDGFB-driven glioma was not well characterized 
with regards to the tumor and microenvironmental signature. Using the RCAS/tv-a mouse 
glioma model we defined PDGFB driven N/tv-a;Arf-/- gliomas and elucidated the functional 
properties of microglia and macrophages.  
In collaboration with a neuropathologist, according to histopathological characteristics of 
human gliomas, PDGFB driven N/tv-a;Arf-/- mouse gliomas were divided into grade II- to 
grade IV-like gliomas, where grade IV-like gliomas showed features of human GBMs. 
Moreover, these low- and high-grade gliomas could be identified as astrocytomas based on 
their expression of GFAP.  
We then continued to elaborate on vessel functionality and analyzed vessel perfusion and 
hypoxia. With increased grade of malignancy the number of perfused vessels was 
significantly decreased while hypoxia was markedly increased. Since pericyte coverage of 
blood vessels is important for vessel maturation and function, we assumed that high-grade 
gliomas have decreased pericyte coverage and immunostained the gliomas with the pericyte 
marker α-smooth muscle actin (α-SMA). Surprisingly, α-SMA+ cells accumulated with 
increased malignancy and these cells were rarely found in conjunction with vessels but 
instead spread throughout the tumors. This finding prompted us to further investigate if those 
α-SMA+ cells were actually pericytes. Therefore, we checked different mesenchymal/pericyte 
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and tumor cell markers and could identify those cells as a subpopulation of tumor cells that 
expressed α-SMA and PDGFRB. 
Considering that α-SMA+ and PDGFRB+ glioma cells were scattered throughout the tumor 
mass, we wondered if these cells were associated to other types of stromal cells, such as 
TAMMs. Indeed, we found IBA1+ TAMMs in close proximity to α-SMA+ and PDGFRB+ 
glioma cells. We then continued investigating PDGFRB expression on glioma cells and their 
co-localization with TAMMs. In concordance, we found increased PDGFRB expression on 
glioma cells in high-grade gliomas compared to low-grade gliomas. Along with this finding 
we observed increased IBA1+ TAMM accumulation that could be correlated to PDGFRB 
expression on glioma cells. Between 50-65% of those glioma cells were in direct physical 
contact to IBA1+ TAMMs.  However, we were curious about how relevant our observations 
in mouse astrocytomas would be for human astrocytomas. Hence, we looked at PDGFRB 
expression on glioma cells and TAMM accumulation in grade II to IV human astrocytomas. 
In fact, we could verify the correlative accumulation of TAMMs and increased PDGFRB 
expression on glioma cells throughout the grades of human astrocytomas (Figure 13). 
 
 
 
 
 
 
 
 
 
 
Figure 13. Mouse and human astrocytomas show increased expression of PDGFRB on glioma cells 
with increased grade of malignancy, which correlates to the accumulation of TAMMs. 
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Based on these results, we hypothesized that TAMMs could induce PDGFRB expression on 
glioma cells. As mentioned earlier, under physiological conditions, microglia are the 
abundant cell type in the brain. However, when pathological malignancies occur, the blood 
brain barrier is disrupted and monocytes can infiltrate the tumor. Therefore, we performed co-
culture experiments with glioma stem cells together with either microglia or BMDMs that 
were polarized to an M1-like phenotype (LPS+IFNγ) or M2-like phenotype (IL-4+TGF-
β+IL-10) ex vivo. To our surprise, only cell-to-cell contact with microglia but not BMDMs 
could induce glioma cells to express PDGFRB. Moreover, even though both M1- and M2-
like microglia could induce PDGFRB expression, M2-like microglia induced significantly 
higher expression levels of this receptor. Importantly, only M2-like microglia were able to 
increase the migratory capacity of glioma cells via the upregulation of PDGFRB. Of note, 
BMDMs that have been pre-conditioned with microglia-derived factors also failed to induce 
PDGFRB expression on glioma stem cells. In conclusion, microglia but not BMDMs induce 
PDGFRB expression on glioma cells and thereby enhance their migratory capacity (Figure 
14).   
 
 
Figure 14. Microglia induce PDGFRB expression on glioma cells and thereby increase their 
migratory capacity. Macrophages fail to induce PDGFRB expression on glioma cells. 
 
The finding that BMDMs failed to induce PDGFRB expression on glioma cells in vitro, 
sheds more light on the functional differences between microglia and macrophages that have 
not been fully discovered yet. This is especially important in therapy treatment because 
approaching these two subpopulations differentially might present new possibilities in glioma 
treatment.      
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4 CONCLUSIONS 
Cancer is a complex disease that involves the immune system at every step of its growth and 
spread to secondary organs. The wide variety of mutations and differential 
microenvironmental signatures that may be encountered throughout the various cancer types 
make it very difficult to successfully treat the disease. Macrophages and microglia are 
abundant cells in all types of cancers. Whether these cells are allies or enemies to cancer 
depends on their microenvironmental surroundings and stimuli. In this thesis we have 
demonstrated the diverse functions of macrophages and microglia in cancer evolvement and 
invasion, and have shown that modulating, rather than depleting distinct subpopulations of 
macrophages and microglia, offers more opportunities to develop successful strategies in 
anti-cancer therapies. Moreover, we have illustrated that there are functional dissimilarities 
between macrophages and microglia. These dissimilarities provide evidence that these two 
populations not only differ ontologically but also behave differentially when interacting with 
tumor cells. These findings may facilitate better understanding of the efficiency and outcome 
of therapy treatments.  
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dem Blick verloren. Es ist schön zu wissen, dass du immer für mich da bist und unsere 
Freundschaft so sehr schätzt. Das bedeutet mir sehr viel. Du und Sven, ihr empfangt mich 
immer mit offenen Armen und lasst es mir an nichts fehlen. Ich möchte mich für alles von 
Herzen bedanken. 
Mike, uns verbindet eine sehr lange Vergangenheit, wo wir sehr viel geteilt, erlebt und 
gelernt haben. Wie das Leben so spielt, sollte es nicht bei dieser Vergangenheit bleiben. Was 
das Leben für uns noch bereit hält, weiß ich nicht, aber wir können es gemeinsam in der 
Gegenwart und Zukunft herausfinden. Danke für all deine Unterstützung, deine selbstlose 
Hilfe und deinen Glauben an mich. Du bringst mich immer zum Lachen und bist für mich da. 
Das alles bedeutet mir sehr viel.  
Desi, ich bin unheimlich froh, dass wir uns wiedergefunden haben. Ich genieße es immer sehr 
mit dir, Dustin und Jayden Zeit zu verbingen und einfach mal ein spontanes Frühstück bei 
Claßen zu genießen. Danke für alles was du für mich getan hast und dafür, dass du immer für 
mich da bist. Mit dir kann ich Lachen und Weinen. Das bedeutet mir sehr viel. 
Olla, Micky, Julia, Bee, Valla, Johann und Markus, jedes Mal wenn wir uns alle treffen, 
haben wir sehr viel Spaß. Es bleibt nie langweilig und es gibt immer sehr viel zu lachen. In 
unserer Runde können wir ausgelassen Blödsinn machen und den Stress drum herum 
vergessen. Danke für all diese ausgelassen Abende, die mich die Probleme immer für ein 
Weilchen vergessen lassen. Ich bin sehr froh euch alle zu haben. 
Ralf Gath, während der Schulzeit begegnet jeder Schüler einem Lehrer, der ihn prägt und auf 
dem Weg „erwachsen zu werden“ interessiert begleitet. Du warst dieser Lehrer für mich. Ich 
bin dir sehr dankbar für all deine Unterstützung. Du hast nie etwas im Gegenzug gefordert. 
Die Volleyball AG war das Highlight meiner Schulzeit und immer das worauf ich mich am 
meisten gefreut habe.  
Martin, wir kennen uns jetzt schon ein paar Jahre, in denen unsere Freundschaft stetig 
gewachsen ist. Es ist immer sehr nett mit dir über Gott und die Welt zu sprechen. Ich danke 
dir für die aktive Interesse an meinem Leben.   
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